Literature DB >> 9645689

Prostaglandin E2, interleukin 1alpha, and tumor necrosis factor-alpha increase human osteoclast formation and bone resorption in vitro.

C S Lader1, A M Flanagan.   

Abstract

Prostaglandin E2 (PGE2) and the cytokines interleukin (IL) 1alpha and tumor necrosis factor (TNF)alpha increase bone resorption in vivo, but the effect of these agents on osteoclastic bone resorption has never been studied in an in vitro human system. Our recently described human bone marrow culture system, in which osteoclasts are generated (vitronectin and calcitonin receptor-positive cells which resorb bone), was used to study the effects of these agents. Addition of indomethacin to macrophage colony-stimulating factor (M-CSF)-treated cultures nearly abolished osteoclast parameters, indicating that prostaglandins are virtually essential for human osteoclast formation. Additionally, PGE2 dose responsively increased osteoclast numbers and bone resorption. The effects of M-CSF and PGE2 are independent, as demonstrated by unaltered PGE2 concentrations in culture supernatants in spite of the dose-responsive increase in osteoclast parameters in response to M-CSF. The generation of osteoclasts in the presence of PGE2 occurred in favor of CD 14-positive macrophage formation. IL 1alpha and TNFalpha increased osteoclast parameters in a dose-responsive manner. Maximum stimulation yielded culture supernatant levels of PGE2 approximately the same as those concentrations of exogenous PGE2 that dramatically induced osteoclast formation. This osteoclast-inducing effect was inhibited both by indomethacin and by the specific inhibitor of inducible prostaglandin G/H synthase, NS398, and this was reversed by addition of exogenous PGE2. These results demonstrate unequivocally that IL 1alpha and TNFalpha enhance human osteoclast formation and suggest that they mediate their effects through PGE2.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9645689     DOI: 10.1210/endo.139.7.6085

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  26 in total

1.  Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density.

Authors:  M T Abreu; V Kantorovich; E A Vasiliauskas; U Gruntmanis; R Matuk; K Daigle; S Chen; D Zehnder; Y-C Lin; H Yang; M Hewison; J S Adams
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

Review 2.  Circulating monocytes: an appropriate model for bone-related study.

Authors:  Y Zhou; H-W Deng; H Shen
Journal:  Osteoporos Int       Date:  2015-07-21       Impact factor: 4.507

Review 3.  Etanercept: therapeutic use in patients with rheumatoid arthritis.

Authors:  L Garrison; N D McDonnell
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 4.  Etanercept (Enbrel): update on therapeutic use.

Authors:  G Spencer-Green
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

5.  Activated macrophages for treating skin ulceration: gene expression in human monocytes after hypo-osmotic shock.

Authors:  O Frenkel; E Shani; I Ben-Bassat; F Brok-Simoni; G Rozenfeld-Granot; G Kajakaro; G Rechavi; N Amariglio; E Shinar; D Danon
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

Review 6.  PUFAs, Bone Mineral Density, and Fragility Fracture: Findings from Human Studies.

Authors:  Amanda B Longo; Wendy E Ward
Journal:  Adv Nutr       Date:  2016-03-15       Impact factor: 8.701

7.  Locally delivered salicylic acid from a poly(anhydride-ester): impact on diabetic bone regeneration.

Authors:  Keisuke Wada; Weiling Yu; Mohamad Elazizi; Sandrine Barakat; Michelle A Ouimet; Roselin Rosario-Meléndez; Joseph P Fiorellini; Dana T Graves; Kathryn E Uhrich
Journal:  J Control Release       Date:  2013-07-01       Impact factor: 9.776

8.  Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture.

Authors:  Y Okada; J A Lorenzo; A M Freeman; M Tomita; S G Morham; L G Raisz; C C Pilbeam
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

Review 9.  The TNF receptor superfamily: role in immune inflammation and bone formation.

Authors:  Xin Cheng; Masa Kinosaki; Ramachandran Murali; Mark I Greene
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

10.  Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts.

Authors:  D O' Gradaigh; D Ireland; S Bord; J E Compston
Journal:  Ann Rheum Dis       Date:  2004-04       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.